Skip to main content
. 2017 Apr 12;83(8):1773–1781. doi: 10.1111/bcp.13270

Figure 3.

Figure 3

Simulations of five rituximab pharmacokinetic profiles using typical pharmacokinetics parameters, (A) increasing CD19 counts (10 to 500 mm−3), (B) increasing serum IgG concentrations (5 to 25 g l–1), and (C) for rituximab courses 1–5 showing time‐dependence of rituximab pharmacokinetics